Anti-mCTLA-4 treatment results in early and late immune response effects in a murine model of colorectal carcinoma

David Draper, Alden Wong, Stacey Roys, Scott Wise, and Maryland Rosenfeld Franklin

2019

AACR Annual Meeting

在临床前研究期间，在调查治疗机制时，单个治疗后时期的肿瘤免疫应答的分析通常是标准的。
The use of a single sampling point for analysis can limit research on new immune modulation therapies as it provides only a partial view into the dynamic nature of the developing immune response in the tumor.
In this study we examined the kinetics of tumor-directed immune infiltration and activation on day 11 and day 17 post-implantation using the CT26 model for colorectal carcinoma.
CT26模型适度响应检查点抑制。为了检查检查点抑制对免疫应答的早期和晚期效果，用抗MCTLA-4处理携带肿瘤的小鼠。肿瘤分析对应于治疗后的第4天和第10天。
分析的终点包括：
- 11 distinct tumor-infiltrating subsets
- CD8+ T cell activation marker expression
- T细胞细胞因子分析
- 效应/内存T细胞表型
我们假设多种采样点将揭示独特的免疫子集特定型渗透和CT26肿瘤活化的特定谱。